New Report Covers Hypertriglyceridemia - Pipeline Review, H1 2016

Hypertriglyceridemia - Pipeline Review, H1 2016 ​is a new market research publication announced by Reportstack. This report provides an overview of the Hypertriglyceridemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hypertriglyceridemia, complete with analysis by stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypertriglyceridemia and features dormant and discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

To view the table of contents and know more details, please visit ​Hypertriglyceridemia - Pipeline Review, H1 2016.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hypertriglyceridemia
- The report reviews pipeline therapeutics for Hypertriglyceridemia by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Hypertriglyceridemia

Reasons to buy

- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hypertriglyceridemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned

Acasti Pharma Inc. Allergan Plc Alnylam Pharmaceuticals, Inc. Arisaph Pharmaceuticals, Inc. AstraZeneca Plc BASF SE Cardax Pharmaceuticals, Inc. Catabasis Pharmaceuticals, Inc. CymaBay Therapeutics, Inc. Jeil Pharmaceutical Co., Ltd. Kyorin Pharmaceutical Co., Ltd. Matinas BioPharma Holdings, Inc. Pharmena SA Sancilio & Company, Inc. Thetis Pharmaceuticals LLC Zydus Cadila Healthcare Limited

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###